# FDA Adds Another Player in ALK-Positive Lung Cancer

Source: [MedPageToday.com - medical news for physicians](https://www.medpagetoday.com/hematologyoncology/lungcancer/123937) · 2026-11-17 · Medicine
Page: https://themorning.science/story/fda-adds-another-player-in-alk-positive-lung-cancer-8318a67cdaf12289
Kind: launch · Impact: medium

## In brief

- The FDA granted accelerated approval to neladalkib, marketed as Nelkarmi, for previously treated advanced ALK-positive non-small cell lung cancer.
- Neladalkib is a third-generation ALK inhibitor and the seventh approved agent for this cancer type, according to MedPage Today.

## Why it matters

It adds another targeted option for patients with ALK-positive lung cancer whose disease has progressed after earlier treatment. Accelerated approval rests on interim evidence, so confirmatory results will matter.

## Coverage

- [FDA Adds Another Player in ALK-Positive Lung Cancer](https://www.medpagetoday.com/hematologyoncology/lungcancer/123937) — MedPageToday.com - medical news for physicians, 2026-11-17

Tags: oncology, lung cancer, alk inhibitor, fda approval, targeted therapy

---

Brief generated by AI (claude-haiku-5-5) from the reporting listed under Coverage. Headlines belong to their publishers. The Morning Science – https://themorning.science
